BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals today announced it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-3200 in late stage cancer patients. VGX-3200 is an injectable DNA plasmid-based therapeutic that expresses human Growth Hormone Releasing Hormone (GHRH) protein. VGX’s innovative DNA delivery technology allows GHRH to be naturally produced and maintained under endogenous physiologic feedback regulation. Treatment for cancer-related cachexia and anemia is the first target for VGX-3200. Additionally, the Company is developing the GHRH technology for a number of other indications including age-related disorders.
